Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma

详细信息    查看全文

• 作者：Kamalvir Gill ; Cheryl Bayart ; Ritu Desai ; Alex Golden ; Patricia Raimer and Joan Tamburro
• 刊名：Pediatric Dermatology
• 出版年：2016
• 出版时间：July/August 2016
• 年：2016
• 卷：33
• 期：4
• 页码：e232-e234
• 全文大小：63K
• ISSN：1525-1470

文摘

Combigan (Allergan, Irvine, CA) is an ophthalmic solution that combines 0.2% brimonidine, a selective α-2 adrenergic agonist, with 0.5% timolol, a nonselective β-adrenergic antagonist. It is approved for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. There have been recent reports of successful treatment of superficial infantile hemangiomas (IHs) using Combigan topically. We report the case of a 2-month-old girl who developed life-threatening brimonidine toxicity requiring intubation and mechanical ventilation secondary to central nervous system depression and apnea after topical application to an ulcerated IH.